| Identification | Back Directory | [Name]
lithospermic acid | [CAS]
28831-65-4 | [Synonyms]
Aids071478
Aids-071478
Clinopodic acid H
lithospermic acid
4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid
(2S,3S)-4-[(E)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylic acid
3-Benzofurancarboxylic acid, 4-[(1E)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxo-1-propen-1-yl]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-, (2S,3S)- | [Molecular Formula]
C27H22O12 | [MDL Number]
MFCD03427311 | [MOL File]
28831-65-4.mol | [Molecular Weight]
538.46 |
| Chemical Properties | Back Directory | [Melting point ]
183-188 °C | [Boiling point ]
862.6±65.0 °C(Predicted) | [density ]
1.642±0.06 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
Soluble in methan | [form ]
powder | [pka]
2.77±0.10(Predicted) | [color ]
White | [Major Application]
food and beverages | [InChIKey]
UJZQBMQZMKFSRV-RGKBJLTCSA-N | [SMILES]
O1C2=C(O)C=CC(/C=C/C(O[C@@H](C(O)=O)CC3=CC=C(O)C(O)=C3)=O)=C2[C@H](C(O)=O)[C@H]1C1=CC=C(O)C(O)=C1 |
| Hazard Information | Back Directory | [Chemical Properties]
Pale yellow crystals, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from the rhizome of Salvia miltiorrhiza, Lithospermum erythrorhizon of the Boraginaceae family. | [Uses]
Shikoric acid has the functions of improving kidney function, preventing and treating cardiovascular diseases, and anti-oxidation. | [Biological Activity]
Lithospermic acid, a plant-derived polycyclic phenolic carboxylic acid isolated from Salvia miltiorrhiza, has antioxidant and hepatoprotective activities against CCl4-induced acute and in vitro liver injury. | [in vivo]
Lithospermic acid (50 mg/kg, po for 6 days) exhibits cardioprotective efficacy against MI/R injury in mouse models[2].
Lithospermic acid (10-30 mg/kg, po, single dose) exhibits uric acid lowering and anti-inflammatory effects in rats hyperuricemia and gouty arthritis models[3].
| Animal Model: | C57BL/6 mouse MI/R injury models[2] | | Dosage: | 50 mg/kg | | Administration: | po for 6 days | | Result: | Improved MI/R-induced cardiac dysfunction. |
| Animal Model: | Hyperuricemia and gouty arthritis model[3] | | Dosage: | 10-30 mg/kg | | Administration: | po, single dose | | Result: | Reduced the serum uric acid and monosodium urate crystal-induced paw edema. |
| [target]
ROS | ERK | MMP(e.g.TIMP) | DNA/RNA Synthesis | Caspase | TNF-α | HIV | SOD | GPx | Xanthine oxidas | MPO | MDA |
|
|